Top 10 Psychedelics Papers of 2020

This psilocybin trial for major depression was one of the most visible clinical papers of the period. It showed rapid symptom reductions after two supported sessions and helped set the agenda for larger, better-controlled depression studies.

Jerome and colleagues pooled long-term follow-up data from six phase 2 MDMA-assisted psychotherapy trials for PTSD. The paper is notable because many participants maintained or deepened gains over time, strengthening the rationale for phase 3 testing.

This pilot study explored psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men. It is interesting because it tests both a neglected population and a more scalable group-support format, while staying appropriately cautious about feasibility data.

Schindler and colleagues tested psilocybin for migraine in a small controlled crossover study. The paper is notable because it extends psychedelic research beyond psychiatric indications and suggests that even moderate dosing may have effects worth studying in headache disorders.

This tabernanthalog paper helped energise the search for non-hallucinogenic psychedelic-inspired compounds. In animal and cellular models, the ibogaine analogue showed plasticity-related and behavioural effects without the same toxicity or psychedelic profile, raising drug-development questions.

Mason and colleagues linked psilocybin, glutamate changes, and ego dissolution in a controlled imaging study. The paper is interesting because it suggests that positive and negative experiences of ego dissolution may relate to different regional neurochemical patterns.

This salvinorin A fMRI study shows that a non-classical hallucinogen can alter brain connectivity in ways that partly resemble other psychedelic states. It is useful because it broadens mechanism debates beyond the serotonin 5-HT2A pathway.

Roth and colleagues resolved how hallucinogens bind and activate the 5-HT2A receptor at a structural level. The paper is technical, but important because receptor structure can guide attempts to design compounds with different therapeutic and subjective profiles.

Kargbo and colleagues describe a scalable cGMP route for manufacturing psilocybin. The paper matters because clinical access depends not only on efficacy, but also on reliable, high-quality production at a scale suitable for trials and eventual care.

Reiff and colleagues synthesise the state of psychedelic-assisted psychotherapy as of early 2020. The review is useful because it brings together evidence across MDMA, psilocybin, LSD, and ayahuasca while outlining clinical, regulatory, and training questions still ahead.